(12-129) Tolerability of Cyclin-Dependent Kinase 4/6 Inhibitors (CDK 4/6i) in Early vs Late-Stage Breast Cancer

Wednesday, December 10, 2025

2:00 PM - 3:00 PM

Location: Bayside A, Level 1

Residency Program: Kettering Health Dayton
Residency Program Type: PGY1 (Pharmacy)
Residency Program Location: Ohio

Co-Author(s): Kathleen Patton, Bethany Sibbitt, Kylie Lang, Julia Dickman

Primary Author(s)